GlassScriptPhysician profile
Lydia Estelle Osterman
NPI 1710700034
$1,243.96
in general payments reported to CMS, 2019-2025
30 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 88% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $170.64 | 2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $136.23 | 2025 | Carvykti, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $80.51 | 2025 | Datroway |
| Abbvie INC. | $60.35 | 2025 | |
| Eisai INC. | $54.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.01 | 2025 | |
| Merck Sharp & Dohme LLC | $48.25 | 2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $47.64 | 2025 | |
| Genmab U.S., INC. | $47.45 | 2025 | Epkinly, Tivdak |
| Stemline Therapeutics INC. | $45.36 | 2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $43.97 | 2025 | Libtayo, Lynozyfic |
| Aveo Pharmaceuticals, INC. | $38.90 | 2025 | |
| Genzyme Corporation | $37.33 | 2025 | |
| Gilead Sciences, INC. | $29.03 | 2025 | Trodelvy |
| Adc Therapeutics America, INC. | $28.75 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.29 | 2025 | Fruzaqla |
| Geron Corporation | $27.25 | 2025 | Rytelo |
| Astellas Pharma US INC | $25.66 | 2025 | Vyloy |
| Alexion Pharmaceuticals, INC. | $25.45 | 2025 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $24.77 | 2025 | Provenge |
| Glaxosmithkline, LLC. | $24.51 | 2025 | Ojjaara |
| Sobi, INC | $22.75 | 2025 | |
| Array Biopharma INC | $21.04 | 2025 | Tukysa, Braftovi, Mektovi |
| Karyopharm Therapeutics INC. | $20.26 | 2025 | Xpovio |
| Emd Serono, INC. | $19.19 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.84 | 2025 | Opdivo |
| Medtronic, INC. | $17.21 | 2025 | Illumisite |
| Lilly USA, LLC | $16.14 | 2025 | Jaypirca, Verzenio |
| Pfizer INC. | $15.79 | 2025 | |
| Agios Pharmaceuticals, INC. | $13.85 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Osterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.